Journal of Clinical Medicine,
Год журнала:
2024,
Номер
13(2), С. 592 - 592
Опубликована: Янв. 19, 2024
Transcatheter
aortic
valve
implantation
(TAVI)
is
now
well
established
as
the
treatment
of
choice
for
patients
with
native
stenosis
who
are
high
or
intermediate
risk
surgical
replacement.
Recent
data
has
also
supported
use
TAVI
in
at
low
and
anatomical
subsets
that
were
previously
felt
to
be
contra-indicated
including
bicuspid
valves
regurgitation.
With
advancements
refinements
procedural
techniques,
application
this
technology
been
further
expanded
include
management
degenerated
bioprosthesis.
After
demonstration
feasibility
safety
bioprosthetic
valves,
mitral
tricuspid
well-established
provides
an
attractive
alternative
performing
redo
surgery.
In
review,
we
appraise
latest
clinical
evidence
highlight
considerations
when
utilising
aortic,
prosthesis.
Canadian Journal of Cardiology,
Год журнала:
2023,
Номер
40(2), С. 316 - 325
Опубликована: Ноя. 26, 2023
Although
transcatheter
aortic
valve
replacement
was
originally
fulfilling
an
unmet
clinical
need
in
the
elderly
population
suffering
from
tricuspid
stenosis,
its
use
has
been
progressively
expanded
to
other
groups
of
patients.
In
this
review,
we
will
focus
on
pure
native
regurgitation,
which
is
most
cases
a
degenerative
disease
and,
therefore
frequently
diagnosed
patients
with
comorbidities.
Symptoms
tend
appear
late
when
left
ventricular
dilation
and
systolic
dysfunction
are
associated
due
excessive
volume
overload.
It
often
combined
dilated
annulus
ascending
aorta.
Surgical
remains
gold
standard
treatment
for
severe
regurgitation.
However,
at
prohibitive
surgical
risk,
represents
attractive
alternative.
Various
technical
challenges
absence
calcium
level
means
no
anchoring
points
nor
fluoroscopic
landmarks,
difficulty
sizing,
increased
stroke
secondary
regurgitation
making
deployment
more
unstable
than
setting
stenosis.
The
first-generation
valves
were
higher
mortality
rate
lower
procedural
success
relation
risk
paravalvular
leak,
migration
requiring
second
or
annular
rupture
recent
off-label
on-label
valves.
Early
studies
dedicated
devices
showed
safety
promising
results
undoubtedly
serve
future
growing
number
surgery.
Catheterization and Cardiovascular Interventions,
Год журнала:
2025,
Номер
unknown
Опубликована: Фев. 5, 2025
ABSTRACT
In
2023–2024,
there
was
a
surge
in
research
on
structural
heart
disease.
This
review
aims
to
provide
comprehensive
overview
of
the
field
for
both
general
and
interventional
cardiologists,
especially
those
with
keen
interest
interventions.
It
summarizes
most
important
randomized
controlled
trials,
meta‐analyses,
retrospective
analyses,
data
registries,
noteworthy
late‐breaking
studies
unveiled
at
prominent
cardiology
conferences.
European Heart Journal Supplements,
Год журнала:
2025,
Номер
27(Supplement_3), С. iii105 - iii110
Опубликована: Март 1, 2025
Abstract
Moderate
or
severe
aortic
insufficiency
(AI)
is
a
relatively
rare
condition
but
with
significant
clinical
implications,
especially
in
elderly
patients
at
high
surgical
risk.
Although
valve
replacement
remains
the
gold
standard
for
treatment,
proportion
of
are
not
eligible
due
to
In
recent
years,
transcatheter
implantation
(TAVI)
has
revolutionized
treatment
stenosis,
its
application
AI
encountered
challenges,
mainly
related
specific
anatomical
characteristics
this
population.
This
review
provides
an
overview
evolution
AI,
highlighting
critical
issues
first-generation
TAVI
devices
and
improvements
achieved
new-generation
dedicated
devices,
such
as
JenaValve
J-Valve.
Preliminary
data
demonstrate
encouraging
procedural
results,
including
reduction
residual
improved
safety
However,
limitations
remain,
incidence
pacemaker
lack
long-term
randomized
trials.
light
technological
advances,
represents
promising
therapeutic
option
selected
if
performed
high-volume
centres
extensive
experience
disease.
